Drug Profile
ODN/Pam2 - Pulmotect
Alternative Names: ODN-M362/Pam2CSK4; Pam2-ODN; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Pulmotect
- Developer Cancer Prevention & Research Institute of Texas; National Heart, Lung and Blood Institute; Pulmotect; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Antisense oligonucleotides; Antivirals; Lipopeptides
- Mechanism of Action Toll like receptor 2 agonists; Toll like receptor 6 agonists; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease; COVID 2019 infections
- No development reported Haematological malignancies; Lung disorders; Pneumocystis pneumonia
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Lung-disorders in USA (Inhalation, Liquid)
- 19 May 2023 Pharmacodynamics and adverse events data from a phase II trial in Chronic obstructive pulmonary disease presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
- 25 Apr 2023 Pulmotect withdraws a phase I trial prior to enrollment for Haematologic malignancies in USA due to revision of development plan (NCT03097796)